Psoriasis. Psoriasis, unspecified
Conditions
Interventions
Intervention 1: The main intervention group: for this group, 2 vials of omalizumab 150 mg per month (total of 300 mg per month) will be injected subcutaneously for 6 times with monthly intervals. The
for each injection, two vials totaling 10 cc will be drawn into a 10 cc syringe and injected intravenously. Patients will be monitored for signs of allergic reaction for 2 hours after injection, and t
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 50 Years
Inclusion criteria
Inclusion criteria: Patients with mild to moderate psoriasis (with PASI more than 10-15 and less than 30-40) with more than 10-15% involvement and whose disease is not so mild and limited to respond to routine topical treatment (they have received routine topical treatment and have not reached the minimum acceptable therapeutic response*), And it was not so severe and extensive that needs severe stage treatments (with too many side effects). *Minimum acceptable therapeutic response: BSA less than 3% or BSA reduction greater than 75% (compared to the time of starting treatment) at 3 months after starting treatment. Patients living in remote area who cannot travel a long distance to receive phototherapy 3 times a week and for a long period of time. 30-50 years old
Exclusion criteria
Exclusion criteria: Prior history of Omalizumab injection Prior history of receiving systemic treatments for psoriasis such as Methotrexate, Ciclosporin, Acitretin, Etanercept, Adalimumab, Infliximab, and Ustekinumab. Prior history of phototherapy Past anaphylaxis history
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Psoriasis Severity. Timepoint: At 5 timepoints, before, during and after intervention (month O, 1, 2, 4, and 6). Method of measurement: Psoriasis Area and Severity Index (PASI). | — |
Secondary
| Measure | Time frame |
|---|---|
| Dermatology Life Quality. Timepoint: Before intervention and after 6 months of intervention. Method of measurement: Dermatology Life Quality Index; DLQI.;Serum Total IgE Level. Timepoint: Before intervention and after 6 months of intervention. Method of measurement: Elisa. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMehraneh Movahedi Aliabadi
Mashhad University of Medical Sciences
Outcome results
None listed